MANEMANENYSE

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

businesswire.com

Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that three abstracts will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting being held in Denver, Colorado on March 27 – 31, 2026. The data to be presented include a blinded, retrospective investigator global as.

seekingalpha.com

Veradermics, Incorporated (MANE) Presents at Leerink Global Healthcare Conference 2026 Transcript

defenseworld.net

Analysts Set MANE (NYSE:MANE) Target Price at $78.33

Shares of MANE (NYSE: MANE - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among

businesswire.com

Veradermics to Participate in Upcoming March Investor Conferences

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced that management will participate in the following upcoming investor conferences in March: Leerink Partners Global Healthcare Conference on Tuesday, March 10 in Miami, FL Reid Waldman, M.D., CEO of Veradermics, will participate in a firesid.

proactiveinvestors.com

Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill

Jefferies is initiating coverage of Veradermics with a 'buy' rating, betting that a smarter formulation of an old drug could unlock a $2 billion market Minoxidil has been around for decades. Millions of people rub it into their scalps every day, and a growing number take low-dose oral versions off-label.

247wallst.com

Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders

Four stocks seeing the most notable insider purchases in the past week or so were biotechs SpyGlass Pharma (NASDAQ: SGP) and Veradermics (NYSE: MANE), as well as KKR (NYSE: KKR) and Reddit (NYSE: RDDT).

prnewswire.com

NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.

gurufocus.com

First Look: Novo sues Hims, BP halts buybacks, Meta faces trial

Stock News Novo sues Hims over compounded weight-loss drugs: Novo Nordisk (NVO) filed suit to stop Hims and Hers Health (HIMS) from selling compounded semaglutide

gurufocus.com

First Look: Amazon's $200B Capex, Coinbase's SB Ad, Kroger CEO

Stock News Japan rally on election landslide: Japanese stocks hit record highs after Prime Minister Sanae Takaichi's coalition secured a two-thirds lower-house

businesswire.com

Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announced completion of enrollment in Veradermics' first Phase 2/3.

seekingalpha.com

U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years

Seven IPOs and six SPACs priced this week. Five IPOs and five SPACs submitted filings. Five IPOs are currently scheduled in the week ahead, and some smaller issuers may join the calendar throughout the week.

businesswire.com

Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the closing of its previously announced upsized initial public offering of 17,339,294 shares of its common stock at an initial public offering price of $17.00 per share, including 2,261,647 shares sold pursuant to the exerc.

gurufocus.com

Market Today: Tech Slump, Google AI Spend, Bitcoin Slide

Guru Stock PicksAzvalor Internacional FI has made the following transactions:Reduce in XMAD: PSG by 98.37%Sold out in BAAdd in XMAD: COL by 6.77%New position in A

businesswire.com

Veradermics Announces Pricing of Upsized Initial Public Offering

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Veradermics. The gross proceeds fro.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance